Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LILRB agonistic antibody (ImmunOs Therapeutics)
- Development stage
- Preclinical
- Lead developer
- ImmunOs Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Retro-orbital, Intraperitoneal, Subcutaneous, Intra-arterial
01
Overview
This preclinical-stage program from ImmunOs Therapeutics AG involves the development of HLA-mimicking, agonistic antibodies designed to target Leukocyte Immunoglobulin-Like Receptor Subfamily B (LILRB) receptors. Utilizing the company's proprietary HLA-based technology platform, these antibodies aim to modulate the innate immune system by agonizing LILRB receptors to dampen overactive immune responses. This approach is specifically tailored for the treatment of inflammatory and autoimmune diseases, contrasting with the company's lead oncology program (IOS-1002), which utilizes LILRB antagonism to stimulate immune responses against tumors.
- Other names
- LILRB receptor targeting moleculesHLA-mimicking agonistic antibodies targeting LILRBHLA-mimicking / agonistic antibodies targeting LILRB
02
Targets
LILRB1 (Leukocyte immunoglobulin-like receptor subfamily B member 1)LILRB2 (Leukocyte immunoglobulin-like receptor subfamily B member 2)LILRB (Leukocyte immunoglobulin-like receptor B family)
Beyond the preview
Go deeper on LILRB agonistic antibody (ImmunOs Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LILRB agonistic antibody (ImmunOs Therapeutics).